195 related articles for article (PubMed ID: 32960509)
1. Proteomic patterns associated with response to breast cancer neoadjuvant treatment.
Shenoy A; Belugali Nataraj N; Perry G; Loayza Puch F; Nagel R; Marin I; Balint N; Bossel N; Pavlovsky A; Barshack I; Kaufman B; Agami R; Yarden Y; Dadiani M; Geiger T
Mol Syst Biol; 2020 Sep; 16(9):e9443. PubMed ID: 32960509
[TBL] [Abstract][Full Text] [Related]
2. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
Ding J; Kuo ML; Su L; Xue L; Luh F; Zhang H; Wang J; Lin TG; Zhang K; Chu P; Zheng S; Liu X; Yen Y
Carcinogenesis; 2017 May; 38(5):519-531. PubMed ID: 28379297
[TBL] [Abstract][Full Text] [Related]
3.
Christensen EM; Bogner AN; Vandekeere A; Tam GS; Patel SM; Becker DF; Fendt SM; Tanner JJ
J Biol Chem; 2020 Dec; 295(52):18316-18327. PubMed ID: 33109600
[TBL] [Abstract][Full Text] [Related]
4. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma.
Gao Y; Luo L; Xie Y; Zhao Y; Yao J; Liu X
Mol Carcinog; 2020 May; 59(5):503-511. PubMed ID: 32133692
[TBL] [Abstract][Full Text] [Related]
5. Proline synthesis through PYCR1 is required to support cancer cell proliferation and survival in oxygen-limiting conditions.
Westbrook RL; Bridges E; Roberts J; Escribano-Gonzalez C; Eales KL; Vettore LA; Walker PD; Vera-Siguenza E; Rana H; Cuozzo F; Eskla KL; Vellama H; Shaaban A; Nixon C; Luuk H; Lavery GG; Hodson DJ; Harris AL; Tennant DA
Cell Rep; 2022 Feb; 38(5):110320. PubMed ID: 35108535
[TBL] [Abstract][Full Text] [Related]
6. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix.
Kay EJ; Paterson K; Riera-Domingo C; Sumpton D; Däbritz JHM; Tardito S; Boldrini C; Hernandez-Fernaud JR; Athineos D; Dhayade S; Stepanova E; Gjerga E; Neilson LJ; Lilla S; Hedley A; Koulouras G; McGregor G; Jamieson C; Johnson RM; Park M; Kirschner K; Miller C; Kamphorst JJ; Loayza-Puch F; Saez-Rodriguez J; Mazzone M; Blyth K; Zagnoni M; Zanivan S
Nat Metab; 2022 Jun; 4(6):693-710. PubMed ID: 35760868
[TBL] [Abstract][Full Text] [Related]
8. Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis.
Sun T; Song Y; Yu H; Luo X
Cancer Biol Ther; 2019; 20(6):760-773. PubMed ID: 30810442
[TBL] [Abstract][Full Text] [Related]
9. PYCR in Kidney Renal Papillary Cell Carcinoma: Expression, Prognosis, Gene Regulation Network, and Regulation Targets.
Shao Z; Lu L; Cui Y; Deng L; Xu Q; Liang Q; Lu X; Zhang J; Chen J; Situ Y
Front Biosci (Landmark Ed); 2022 Dec; 27(12):336. PubMed ID: 36624948
[TBL] [Abstract][Full Text] [Related]
10. Pyrroline-5-Carboxylate Reductase 1 Accelerates the Migration and Invasion of Nonsmall Cell Lung Cancer
Sang S; Zhang C; Shan J
Cancer Biother Radiopharm; 2019 Aug; 34(6):380-387. PubMed ID: 30916574
[No Abstract] [Full Text] [Related]
11. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
Craze ML; Cheung H; Jewa N; Coimbra NDM; Soria D; El-Ansari R; Aleskandarany MA; Wai Cheng K; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2018 Jan; 118(2):258-265. PubMed ID: 29169183
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma.
Xu Y; Zuo W; Wang X; Zhang Q; Gan X; Tan N; Jia W; Liu J; Li Z; Zhou B; Zhao D; Xie Z; Tan Y; Zheng S; Liu C; Li H; Chen Z; Yang X; Huang Z
Int J Biol Sci; 2021; 17(9):2223-2239. PubMed ID: 34239351
[TBL] [Abstract][Full Text] [Related]
13. PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer.
Zhuang J; Song Y; Ye Y; He S; Ma X; Zhang M; Ni J; Wang J; Xia W
J Transl Med; 2019 Oct; 17(1):343. PubMed ID: 31619254
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA hsa-miR-150-5p inhibits nasopharyngeal carcinogenesis by suppressing PYCR1 (pyrroline-5-carboxylate reductase 1).
Li Z; Zhou X; Huang J; Xu Z; Xing C; Yang J; Zhou X
Bioengineered; 2021 Dec; 12(2):9766-9778. PubMed ID: 34696668
[TBL] [Abstract][Full Text] [Related]
15. The clinical significance of PYCR1 expression in renal cell carcinoma.
Weijin F; Zhibin X; Shengfeng Z; Xiaoli Y; Qijian D; Jiayi L; Qiumei L; Yilong C; Hua M; Deyun L; Jiwen C
Medicine (Baltimore); 2019 Jul; 98(28):e16384. PubMed ID: 31305441
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis.
Hollinshead KER; Munford H; Eales KL; Bardella C; Li C; Escribano-Gonzalez C; Thakker A; Nonnenmacher Y; Kluckova K; Jeeves M; Murren R; Cuozzo F; Ye D; Laurenti G; Zhu W; Hiller K; Hodson DJ; Hua W; Tomlinson IP; Ludwig C; Mao Y; Tennant DA
Cell Rep; 2018 Mar; 22(12):3107-3114. PubMed ID: 29562167
[TBL] [Abstract][Full Text] [Related]
17. Sublethal endoplasmic reticulum stress caused by the mutation of immunoglobulin heavy chain-binding protein induces the synthesis of a mitochondrial protein, pyrroline-5-carboxylate reductase 1.
Jin H; Komita M; Koseki H; Aoe T
Cell Stress Chaperones; 2017 Jan; 22(1):77-85. PubMed ID: 27796797
[TBL] [Abstract][Full Text] [Related]
18. Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.
Oudaert I; Satilmis H; Vlummens P; De Brouwer W; Maes A; Hose D; De Bruyne E; Ghesquière B; Vanderkerken K; De Veirman K; Menu E
J Exp Clin Cancer Res; 2022 Feb; 41(1):45. PubMed ID: 35105345
[TBL] [Abstract][Full Text] [Related]
19. Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.
Loayza-Puch F; Rooijers K; Buil LC; Zijlstra J; Oude Vrielink JF; Lopes R; Ugalde AP; van Breugel P; Hofland I; Wesseling J; van Tellingen O; Bex A; Agami R
Nature; 2016 Feb; 530(7591):490-4. PubMed ID: 26878238
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of PYCR1 suppressed the malignant phenotype of human hepatocellular carcinoma cells via inhibiting the AKT pathway activation.
Guo J; Cheng X; Tian Y; Li B; Zhang X; Gao X; An Y
Reprod Biol; 2021 Sep; 21(3):100534. PubMed ID: 34271243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
